REGN Regeneron Pharmaceuticals Loading...

From COR earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
13:30
Feb 04 ◎
Bob Mosh President and CEO, Cencora, Inc. COR Q1 FY26 call
RCA's better-than-expected performance and high clinical trial contribution suggests accelerated adoption of cell-based gene therapies and biosimilars in retina care, a leading indicator for pharmaceutical suppliers. — Indicates that physician education via MSOs is driving faster biosimilar uptake, which could pressure innovator drug revenues sooner.
REGN
MED

About REGN Analyst Coverage

Buzzberg tracks REGN (Regeneron Pharmaceuticals) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Bob Mosh.